Antiherpes peptide derivatives having a 1,4-dioxo c n-terminus
CA 2018801 C · Owner: Deziel, Robert · Inventors: Moss, Neil; Deziel, Robert; Beaulieu, Pierre Louis
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Disclosed herein are peptide derivatives of the formula R1NH-CO-Q-C(O)-NR2-CHCH2C(O)-Y-C(O)-NH-CHCR3(R4)-COOH- C(W)-NH-CHR5-Z wherein R1 is an optionally substituted alkyl or optionally substituted phenylalkyl, R2 is hydrogen or alkyl R3 and R4, each independently is hydrogen or alkyl or R3 and R4 are joined to, form a cycloalkyl R5 is alkyl, cycloalkyl or (cycloalkyl)alkyl Q is, a divalent radical, for example, -CH2CH2- -CH=CH- or , 1,2-cyclohexanediyl, which serves as a two carbon spacer W is oxo or, thioxo, Y is, for example an alkoxy or a monosubstituted or, disubstituted amino and Z is a terminal unit, for example, hydrogen COOH or CH2OH. The derivatives are useful for treating herpes …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 12, 1990 and granted August 22, 2000. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended June 12, 2010.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 12, 2012.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.